Sentences with phrase «of myeloma patients»

Innovative approaches to harness the immune system to fight multiple myeloma and stimulate a «host - vs - myeloma» effect will benefit the majority of myeloma patients.

Dr Matt Kaiser, Head of Research at Bloodwise, said, «Myeloma is a devastating cancer that can cause debilitating and painful bone damage and, although we have become better at treating it and extending the lives of myeloma patients, it is ultimately almost always fatal.

The prognosis of myeloma patients with EMD behaves like other metastatic cancers and is extremely poor because its clinical course is very aggressive, Tse said.

Researchers used tissue and blood samples to show that the gammopathy (a precursor to myeloma) in both mice and patients with Gaucher disease is triggered by specific lipids, and that the antibodies made by tumor cells in nearly a third of myeloma patients are directed against such lipids.

Not exact matches

Speaking of checkpoint inhibitor drugs... Merck's star cancer immunotherapy treatment Keytruda is facing some troubling clinical trial incidents which have now compelled the Food and Drug Administration (FDA) to halt three studies of the drug in multiple myeloma, a rare blood cancer, after a number of patient deaths.

To participate in the study, which concludes in July 2020, patients must be 18 years or older and have a histological - or cytological - proven diagnosis of a malignancy in the lung, breast, head and neck, genitourinary organs or ovaries or multiple myeloma.

Empliciti will be used in combination with two other drugs to treat patients with multiple myeloma who have received one to three prior courses of medication.

Diagnosed himself with myeloma in April 2015, Tony infuses All4Cure with an incredible sense of urgency to improve the prospects for cancer patients now and in the future.

THE PATIENT AS INNOVATOR With Deborah Brooks of The Michael J. Fox Foundation for Parkinson's Research; Kathy Giusti of the Multiple Myeloma Research Foundation & Consortium; Sean Lane of Crosschx; Claudia Williams of the White House Office of Science and Technology Policy; Rik Kirkland, of McKinsey & Co. — Report by Kia Kokalitcheva — Video: Patients Should Get Access to Their Health Data

The mission of the Multiple Myeloma Research Foundation (MMRF) is to accelerate next generation multiple myeloma treatments to extend patients» lives in pursuit of Myeloma Research Foundation (MMRF) is to accelerate next generation multiple myeloma treatments to extend patients» lives in pursuit of myeloma treatments to extend patients» lives in pursuit of a cure.

Whether one dollar or one thousand, your gift is helping LLS's mission to cure leukemia, lymphoma, Hodgkin's Disease, and myeloma as well as improve the quality of life of patients and their families.

«Choice of medical center impacts life expectancy of multiple myeloma patients, study shows.»

Thirty to 50 percent of multiple myeloma patients have extra copies of the gene that encodes the enzyme ADAR1.

Analyzing a database of nearly 800 multiple myeloma patient samples, they discovered that 162 patients with low ADAR1 levels in their tumor cells survived significantly longer over a three - year period compared to 159 patients with high ADAR1 levels.

«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Health.

«Despite new therapies, it's virtually inevitable that a patient with multiple myeloma will experience relapse of the disease at some point,» said senior author Catriona Jamieson, MD, PhD, professor of medicine, Koman Family Presidential Endowed Chair in Cancer Research and chief of the Division of Regenerative Medicine at UC San Diego School of Medicine.

Notably, the mechanism was clearly associated with poor outcome in patients with the blood cancer myeloma, where proteasome inhibitors are a mainstay of treatment.

Figure on the right: Bortezomib treatment is significantly less effective in multiple myeloma patients who have suppressed expression of a 19s proteasome cap subunit.

The new findings build on prior research from the Dhodapkar lab demonstrating that patients with Gaucher disease, an inherited lipid storage disorder, have a significant increased risk for developing myeloma; and the discovery of a subset of lipid - reactive immune cells, called type II NKT - TFH, that promote the development of plasma cells.

«These studies set the stage for newer approaches to lower the levels of these lipids in patients with Gaucher disease and others with precursors for myeloma.

With multiple myeloma, most patients live four to seven years from their date of diagnosis, and most become resistant to chemotherapy drugs over time.

In a trio of studies to be presented at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition in Orlando, investigators at Dana - Farber Cancer Institute will present the results of clinical trials showing that new drug combinations can significantly extend the time in which multiple myeloma is kept in check in patients with relapsed or treatment - resistant forms of the disease.

Furthermore, the levels of Runx2 expression among a larger group of 351 newly diagnosed multiple myeloma patients were significantly higher in patients who had a high risk of early disease - related death, as compared with lower - risk patients.

Of 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma - related proteins in the blood declines by more than 90 percenOf 32 patients participating in the trial, 11 had a partial response to the drug regimen, meaning a decrease in the extent of the cancer, and 53 had a very good partial response, meaning the level of certain myeloma - related proteins in the blood declines by more than 90 percenof the cancer, and 53 had a very good partial response, meaning the level of certain myeloma - related proteins in the blood declines by more than 90 percenof certain myeloma - related proteins in the blood declines by more than 90 percent.

«In summary, these encouraging data build upon the real success of our translational efforts in myeloma over the last decade, and provide exciting new options with the real promise of improving patient outcome,» said Richardson, who is also the R.J. Corman professor at Harvard Medical School.

«Today, we have half a dozen drugs for multiple myeloma that can put patients into remission,» said Tomasson, who treats patients with multiple myeloma at Siteman Cancer Center at Barnes - Jewish Hospital and Washington University School of Medicine.

But the relationship between multiple myeloma and the BMI of obese and morbidly obese patients was drastic.

These studies enrolled a total of 12,361 patients diagnosed with a variety of cancers, including lung, breast, skin, and prostate, as well as blood cancers such as leukemia, lymphoma, and myeloma.

All of the patients in the three trials had myeloma that had either relapsed or become resistant to other therapies.

«Patients who drew a round body shape had a higher incidence of multiple myeloma.»

Fat cells cultured from the body mass index of a morbidly obese patient cause multiple myeloma cells to anchor to a much greater extent than normal cells and produce a significantly larger number of blood vessels to sustain the cancer cells.

«This suggests that Runx2 levels in myeloma cells may be a gene predictor of a patient's prognosis, good or bad,» Yang said.

In humans, a comparison of bone marrow from 14 normal bone marrow donors, 35 multiple myeloma patients and 11 patients with a noncancerous condition called monoclonal gammopathy of undetermined significance (MGUS) showed that Runx2 levels were significantly higher in the multiple myeloma cells.

Whether investigating fat cells, immunotherapy or use of the CRISPR - Cas 9 gene - editing tool, which a federal panel recently approved for a select number of patients suffering from three types of cancers, including multiple myeloma, approaches beyond attacking cancer cells are needed in the fight against many cancers.

Overweight and obese MGUS patients had a 55 percent and 98 percent higher risk of progression to multiple myeloma, respectively, than normal - weight MGUS patients.

«Based on our finding that being overweight or obese is a risk factor for multiple myeloma in MGUS patients, and since extra weight is a modifiable risk factor, we hope that our results will encourage intervention strategies to prevent the progression of this condition to multiple myeloma as soon as MGUS is diagnosed,» Chang said.

Tse and the team analyzed the degree of expression of AF1q in 117 patients with multiple myeloma.

Approximately 25 percent of patients with multiple myeloma also simultaneously develop extramedullary disease.

«There are clearly molecular differences between African - American and Caucasian multiple myeloma cases, and it will be critical to pursue these observations to better improve clinical management of the disease for all patients,» said John D. Carpten, senior author of the study and chair of the Department of Translational Genomics at the Keck School of Medicine.

A randomized phase III trial finding that a new monoclonal antibody, elotuzumab, added to standard therapy, extended the duration of remission for patients with relapsed multiple myeloma by about five months Findings from two phase III studies showing that children with Wilms tumor who have a specific chromosomal abnormality do better with a more intensive, augmented chemotherapy regimen

Researchers analyzed the genetic sequencing data of 718 multiple myeloma patients and found that African - Americans had increased mutations in the genes BCL7A, BRWD3 and AUTS2, while white people had more mutations in the genes TP53 and IRF4.

A new study published online by JAMA Oncology examines the assessment of minimal residual disease in patients newly treated for multiple myeloma as a factor in survival outcomes.

«Effect of follow - up of MGUS on survival in patients with multiple myeloma.»

Trial # 3: Combined autophagy and proteasome inhibition: A phase 1 trial of HCQ and bortezomib in patients with relapsed / refractory myeloma

And while 50 % of patients experienced a relapse of their myeloma, the subsequent treatment showed marked efficacy: 50 % of these patients were alive five years after the relapse.

Patients with multiple myeloma (MM) appear to have better survival if they are found to have monoclonal gammopathy of undetermined significance (MGUS) first, the state that precedes MM and which is typically diagnosed as part of a medical workup for another reason, according to a study published online by JAMA Oncology.

In its first clinical trial, a breakthrough antibody therapy produced at least partial remissions in a third of patients with multiple myeloma who had exhausted multiple prior treatments, investigators at Dana - Farber Cancer Institute and other organizations report today online in the New England Journal of Medicine.

The authors speculate the reasons for the prolonged survival in their study is that patients with MGUS are evaluated more often for signs of progression to MM and may be diagnosed and started on therapy for myeloma at an earlier stage.

Researchers at MIT have now shown that they can use a new type of measurement to predict how drugs will affect cancer cells taken from multiple - myeloma patients.

Half of multiple myeloma patients diagnosed in the earliest stage of the disease don't survive beyond about five years after initial treatment because the cancer becomes resistant to treatments.